CD19+CD38+调节性B细胞可作为初治成人ITP激素缓解的探索性预后标志物
该前瞻性队列研究纳入37例新诊断原发ITP成人患者,均接受标准化地塞米松方案,用流式细胞术定量CD19+CD38+ B细胞并评估12周疗效。完全缓解率43%,激素难治57%;多因素分析显示基线CD19+CD38+细胞比例较高独立预测激素诱导缓解(p<0.001),ROC曲线确定预测缓解的 cut-off 值为>2.6%(p=0.001)。
要点
- 基线CD19+CD38+ B细胞比例较高独立预测ITP激素缓解(p<0.001)。
- ROC分析确定预测缓解的 cut-off 值为>2.6%(p=0.001)。
- 该标志物为探索性,尚需进一步验证后用于临床决策。
核心结论
- 基线CD19+CD38+ B细胞水平可能作为预测ITP患者激素反应的生物标志物。
主要发现
- 完全缓解率为43%,激素难治性疾病占57%。
- 单因素分析显示基线血小板计数、出血表现、年龄和缓解时间为显著因素。
- 多因素分析显示基线CD19+CD38+细胞比例较高独立预测激素诱导缓解(p<0.001)。
- ROC分析确定预测缓解的 cut-off 值为>2.6%(p=0.001)。
关键数值与推荐
- CD19+CD38+ B细胞预测激素缓解的 cut-off 值为>2.6%(p=0.001)。
临床怎么用
- 基线CD19+CD38+ B细胞比例或可辅助识别可能从激素治疗中获益的初治成人ITP患者。
局限性
- 样本量较小(37例),单中心,标志物为探索性,需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Corticosteroids are commonly used as first-line therapy for immune thrombocytopenia (ITP) to suppress immune-mediated platelet destruction. However, some patients fail to respond, and prolonged use is associated with significant adverse effects, necessitating alternative therapeutic modalities. The aim of this study was to evaluate the role of Cluster of differentiation (CD)19+CD38+ B cells with presumed regulatory potential as exploratory prognostic markers of steroid-induced response in treatment-naïve adult ITP patients. This prospective cohort study included 37 adults with newly diagnosed primary ITP treated with a standardised dexamethasone regimen at a single centre between November 2021 and June 2023. CD19+CD38+ B cells were quantified using flow cytometry. Treatment response at 12 weeks was assessed. Multivariate logistic regression analysis was performed to determine independent prognostic markers of response. Complete response was achieved in 43% of patients, while 57% had steroid-refractory disease. Univariate analysis identified baseline platelet count, bleeding manifestations, age and response time as significant factors. Multivariate analysis demonstrated that a higher baseline percentage of CD19+CD38+ cells independently predicted steroid-induced remission (p < 0.001). Receiver operating characteristic (ROC) analysis identified a cut-off value >2.6% for predicting remission (p = 0.001). Baseline CD19+CD38+ B-cell levels may serve as a useful biomarker for predicting steroid response in ITP.
引用
- Elbayoumi NM, Denewer MA, Khaled O, et al. CD19+ CD 38+ regulatory B lymphocytes as exploratory prognostic markers of steroid-induced remission in treatment-naïve adult immune thrombocytopenia. Br J Haematol. 2026. PMID: 42893847. doi:10.1111/bjh.70895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。